Improves PFS and OS in HER2-positive uterine serous carcinoma (mPFS: 29.6 months, mOS: 12.9 months) vs chemo alone (mPFS: 8 months, mOS: 24.4 months). The gene discussed is ERBB2; the disease is endometrial serous adenocarcinoma.